193 related articles for article (PubMed ID: 28540420)
21. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
22. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814
[TBL] [Abstract][Full Text] [Related]
23. Maintenance hormonal therapy after treatment with medroxyprogesterone acetate for patients with atypical polypoid adenomyoma.
Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Kanao H; Kato K; Utsugi K; Takeshima N
Jpn J Clin Oncol; 2018 Mar; 48(3):255-258. PubMed ID: 29351618
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Whitney CW; Brunetto VL; Zaino RJ; Lentz SS; Sorosky J; Armstrong DK; Lee RB;
Gynecol Oncol; 2004 Jan; 92(1):4-9. PubMed ID: 14751130
[TBL] [Abstract][Full Text] [Related]
25. Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo.
Ochnik AM; Moore NL; Jankovic-Karasoulos T; Bianco-Miotto T; Ryan NK; Thomas MR; Birrell SN; Butler LM; Tilley WD; Hickey TE
Menopause; 2014 Jan; 21(1):79-88. PubMed ID: 23715406
[TBL] [Abstract][Full Text] [Related]
26. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic parameters and immunohistochemical study of endometrial stromal sarcomas.
Wu TI; Chou HH; Yeh CJ; Hsueh S; Yang JE; Jao MS; Chang TC; Hsu CS; Lin KH; Lai CH
Int J Gynecol Pathol; 2013 Sep; 32(5):482-92. PubMed ID: 23896713
[TBL] [Abstract][Full Text] [Related]
28. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Zaino RJ; Brady WE; Todd W; Leslie K; Fischer EG; Horowitz NS; Mannel RS; Walker JL; Ivanovic M; Duska LR
Int J Gynecol Pathol; 2014 Nov; 33(6):543-53. PubMed ID: 25272292
[TBL] [Abstract][Full Text] [Related]
29. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
30. The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells.
Ghatge RP; Jacobsen BM; Schittone SA; Horwitz KB
Breast Cancer Res; 2005; 7(6):R1036-50. PubMed ID: 16457685
[TBL] [Abstract][Full Text] [Related]
31. Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma.
Watanabe J; Watanabe K; Jobo T; Kamata Y; Kawaguchi M; Imai M; Okayasu I; Kuramoto H
Int J Gynecol Cancer; 2006; 16 Suppl 1():452-7. PubMed ID: 16515645
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
33. [Conservative treatment of endometrial cancer as a way to preserve fertility. Five-year experience at Instituto Nacional de Perinatilogía Isidro Espinoza de los Reyes].
Arteaga Gómez AC; Castellanos Barroso G; Márquez Acosta G
Ginecol Obstet Mex; 2012 Jun; 80(6):394-9. PubMed ID: 22826967
[TBL] [Abstract][Full Text] [Related]
34. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
35. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
[TBL] [Abstract][Full Text] [Related]
36. [Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)].
Nishio S; Koyanagi T; Miyabe K; Kuromatsu H
Gan To Kagaku Ryoho; 2010 Apr; 37(4):735-8. PubMed ID: 20414038
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
Covens AL; Filiaci V; Gersell D; Lutman CV; Bonebrake A; Lee YC
Gynecol Oncol; 2011 Feb; 120(2):185-8. PubMed ID: 21075433
[TBL] [Abstract][Full Text] [Related]
38. [Two cases of endometrial stromal sarcoma (ESS) in which survival was prolonged by administration of MPA].
Ishibashi M; Nakayama K; Shamima Y; Katagiri A; Iida K; Nakayama N; Miyazaki K
Gan To Kagaku Ryoho; 2008 May; 35(5):857-61. PubMed ID: 18487930
[TBL] [Abstract][Full Text] [Related]
39. [Hormone therapy for uterine corpus cancer--introduction].
Sugiyama T; Izutsu T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():370-4. PubMed ID: 15535270
[No Abstract] [Full Text] [Related]
40. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
Minaguchi T; Nakagawa S; Takazawa Y; Nei T; Horie K; Fujiwara T; Osuga Y; Yasugi T; Kugu K; Yano T; Yoshikawa H; Taketani Y
Cancer Lett; 2007 Apr; 248(1):112-22. PubMed ID: 16919866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
